What California statute governs SUD Outpatient Program licensing and when does unlicensed operation trigger CCP § 1021.5?

Health & Safety Code § 11834.11 (administered by the California Department of Health Care Services — DHCS) requires an active DHCS SUD outpatient program license for any entity that provides outpatient substance use disorder treatment services, including individual and group counseling, medication-assisted treatment (MAT) with buprenorphine/naloxone, and ASAM Level 1.0 or Level 2.1 intensive outpatient services. Unlicensed SUD outpatient operation violates § 11834.11 and may support CCP § 1021.5 fee-shifting when enforcement vindicates the significant public right of protecting California patients with opioid use disorder and other SUDs from unlicensed programs that dispense buprenorphine without DEA DATA waiver authorization, lack ASAM Level of Care assessments, and bill Drug Medi-Cal for services provided without DHCS licensure.

How does SAMHSA TIP 63 serve as PURE KETCHUM advisory evidence in a § 11834.11 SUD Outpatient fee petition?

SAMHSA Treatment Improvement Protocol (TIP) 63: Medications for Opioid Use Disorder (2021 Edition, Updated 2024) — published by SAMHSA (founded 1992, Rockville MD) — establishes the federal clinical guidance baseline for MOUD in DHCS-licensed outpatient settings. Part 1 (active DHCS SUD outpatient license as prerequisite to buprenorphine prescribing within a licensed setting), Part 2 Chapter 3C (ASAM Level 1.0 and 2.1 criteria for outpatient and intensive outpatient patient placement), and Part 3 Chapter 5 (urine drug screening frequency, treatment plan update intervals, and medication interaction assessment) are PURE KETCHUM advisory evidence — federal clinical guidance establishing the SUD outpatient treatment baseline that unlicensed operators lack, not independent fee-shifting statutes. DISTINCT from SAMHSA TIP 65 (used for §11834.01 Residential Treatment).

How does the ASAM OBOT and Outpatient SUD Treatment Standards of Care serve as PURE KETCHUM advisory evidence?

The ASAM Standards of Care for the Addiction Specialist Physician in OBOT and Outpatient SUD Treatment (2023 Edition) — published by ASAM (founded 1954, Chevy Chase MD) — establish the addiction medicine physician and practitioner baseline for outpatient SUD care. Standard 1 (active DHCS SUD outpatient license as prerequisite to all Drug Medi-Cal-reimbursed services), Standard 3 (individualized ASAM Criteria Level of Care assessment for patient placement), and Standard 6 (buprenorphine/naloxone induction, DEA DATA waiver compliance, and OBOT patient monitoring) are PURE KETCHUM advisory evidence — DISTINCT from CARF (used for §11834.01 Residential) as the addiction medicine professional society's clinical conduct standards.

What is the estimated annual billing gap for a solo attorney handling § 11834.11 unlicensed SUD Outpatient cases?

The estimated billing gap is 13.25 hours per matter: Gap 1 (DHCS SUD outpatient license verification; SAMHSA TIP 63 Parts 1/2/3 review; ASAM Standards 1/3/6 review; client intake; § 11834.11 violation analysis; Drug Medi-Cal billing records; patient harm documentation — 5.25 hrs); Gap 2 (Ketchum lodestar memo; CCP § 1021.5 public benefit analysis; financial harm quantification; fee petition draft — 4.00 hrs); Gap 3 (Welch declaration; Jenkins fees-on-fees memo; DHCS records; Drug Medi-Cal records; patient care records; hearing prep — 4.00 hrs). At $300–$500/hr: $3,975–$6,625 per matter annually.

California DHCS Licensed Substance Use Disorder Outpatient Program Health & Safety Code § 11834.11 Attorney Fee Petition Mechanics

Governing Statute & License Authority

Health & Safety Code § 11834.11 — DHCS SUD Outpatient Program License
Administered by the California Department of Health Care Services (DHCS), Drug Policy and Programs Division. Primary license verification: DHCS SUD Program Licensing at dhcs.ca.gov. Health & Safety Code § 11834.11 requires an active DHCS SUD outpatient program license for any entity that provides outpatient substance use disorder (SUD) treatment services to two or more individuals. Licensed SUD outpatient programs under § 11834.11 include: (1) ASAM Level 1.0 — Outpatient Services: structured outpatient group and individual counseling, typically fewer than 9 hours per week of service intensity, including SUD assessment, individual therapy, group therapy, case management, and medication support for clients with alcohol use disorder (AUD), opioid use disorder (OUD), stimulant use disorder, and co-occurring mental health conditions; (2) ASAM Level 2.1 — Intensive Outpatient Program (IOP): 9 or more hours per week of structured treatment including multi-hour group therapy sessions, individual counseling, family therapy, medication management, and co-occurring disorder treatment — for clients who require more support than standard outpatient but do not require residential care; (3) Drug Medi-Cal Organized Delivery System (DMC-ODS) Programs: DHCS-contracted SUD outpatient programs serving Medi-Cal beneficiaries in participating counties — subject to DHCS program standards for certified counselors, Drug Medi-Cal billing requirements, and DHCS quality oversight; (4) Office-Based Opioid Treatment (OBOT) Integration: DHCS-licensed SUD outpatient programs that integrate buprenorphine/naloxone (Suboxone) prescribing and dispensing within the licensed outpatient treatment setting — the prescriber must hold an active DEA DATA waiver (Drug Addiction Treatment Act of 2000 waiver, now operating under the Mainstreaming Addiction Treatment Act of 2022) authorizing buprenorphine prescribing for OUD. The DHCS SUD outpatient license under § 11834.11 is distinct from the DHCS SUD Residential Treatment license under § 11834.01, which covers 24-hour residential services, and from the DHCS Narcotic Treatment Program (Opioid Treatment Program) license under § 11839.20, which covers methadone dispensing clinics.

Section 11834.11 establishes that providing SUD outpatient treatment services without an active DHCS license is unlawful and subjects operators to administrative action, civil enforcement, and Drug Medi-Cal fraud liability. The endemic unlicensed SUD outpatient pattern involves operators who establish what they characterize as "wellness centers," "recovery coaching centers," or "holistic healing programs" providing individual and group counseling sessions to clients with opioid use disorder, alcohol use disorder, or other SUDs — without obtaining the DHCS SUD outpatient license that would require DHCS-certified counselors, individualized treatment plans based on DSM-5-TR SUD diagnoses, ASAM Level of Care assessments, Drug Medi-Cal billing compliance, and the DEA DATA waiver authorization that is required before any licensed program setting may integrate buprenorphine prescribing. The result is that individuals with serious SUDs — including OUD patients who require medications for opioid use disorder (MOUD) — receive clinical services without any of the quality, safety, and oversight infrastructure that DHCS SUD outpatient licensing is designed to ensure, creating systemic risk of overdose, medication diversion, and Drug Medi-Cal fraud.

THE ONLY California DHCS Licensed SUD Outpatient Program § 11834.11 Page in This Series

This is THE ONLY California DHCS Licensed Substance Use Disorder Outpatient Program Health & Safety Code § 11834.11 fee-petition-mechanics page in the ClaimHour fee-petition-mechanics series.

DISTINCT FROM: DHCS Licensed SUD Residential Treatment Program (H&S Code § 11834.01 — residential treatment license covers 24-hour residential SUD treatment in a facility setting including room, board, and structured residential programming; residential services require 24-hour staff supervision and cannot be provided as outpatient services) / DHCS Licensed Narcotic Treatment Program (Opioid Treatment Program) (H&S Code § 11839.20 — NTP/OTP license covers methadone dispensing clinics that administer or dispense opioid agonist medications including methadone and buprenorphine through a licensed, federally certified opioid treatment program; the NTP license structure is distinct from the SUD outpatient program license that covers OBOT buprenorphine prescribing in office-based settings) / Licensed Clinical Social Worker (LCSW) (Bus. & Prof. Code § 4996 — individual LCSW license covers individual therapy and counseling by a licensed clinical social worker; an individual LCSW providing SUD counseling to multiple clients within an organizational structure requires both individual licensure and organizational DHCS SUD outpatient program licensing if the organization provides SUD treatment) / Licensed Professional Clinical Counselor (LPCC) (Bus. & Prof. Code § 4999.20 — individual LPCC license covers clinical counseling; same organizational licensing requirements apply) / Licensed Marriage and Family Therapist (MFT) (Bus. & Prof. Code § 4980 — individual MFT license covers marriage, family, and individual therapy; same organizational licensing requirements apply for SUD treatment programs)

Private Professional Standards Advisories PURE KETCHUM

THE ONLY PAGE IN THE FEE-PETITION-MECHANICS SERIES WITH A SAMHSA TIP 63 MEDICATIONS FOR OPIOID USE DISORDER ADVISORY

SAMHSA Treatment Improvement Protocol (TIP) 63: Medications for Opioid Use Disorder (2021 Edition, Updated 2024)
Substance Abuse and Mental Health Services Administration (SAMHSA) — founded 1992, Rockville, MD — the federal agency within the U.S. Department of Health and Human Services (HHS) that leads public behavioral health efforts, including setting clinical treatment standards for substance use disorder and mental health conditions. SAMHSA's Treatment Improvement Protocol (TIP) series represents the federal government's evidence-based clinical guidance for SUD treatment, developed through expert consensus panels of addiction medicine physicians, behavioral health clinicians, and public health researchers. TIP 63 specifically addresses Medications for Opioid Use Disorder (MOUD) — the evidence-based use of buprenorphine/naloxone, methadone, and extended-release naltrexone in outpatient SUD treatment settings. SAMHSA TIP 63 is DISTINCT from SAMHSA TIP 65 (Treating Substance Use Disorder in Adults — used for § 11834.01 Residential Treatment pages in this series): TIP 63 focuses specifically on medications for OUD in outpatient and office-based settings, while TIP 65 focuses on SUD treatment broadly across residential and intensive levels of care. Together with the ASAM Standards of Care, these two separate federal and professional society publications establish the SUD outpatient clinical baseline from two distinct perspectives — federal public health agency guidance (SAMHSA TIP 63) and addiction medicine professional society clinical standards (ASAM).

SAMHSA TIP 63 Part 1 — Active DHCS SUD Outpatient License as Prerequisite to Buprenorphine Prescribing and Dispensing Within a DHCS-Licensed Setting: Establishes the regulatory framework within which buprenorphine/naloxone may be prescribed and dispensed as a MOUD intervention for OUD patients in California outpatient treatment settings. SAMHSA TIP 63 Part 1 provides that: (a) buprenorphine prescribing for OUD within a DHCS-licensed SUD outpatient program setting requires that the organizational provider — the program — hold an active DHCS SUD outpatient license under § 11834.11 and that the prescribing physician, nurse practitioner, or physician assistant hold an active DEA DATA waiver (now operating under the simplified DEA registration system established by the Mainstreaming Addiction Treatment Act of 2022); (b) dispensing or directly administering buprenorphine within a SUD outpatient treatment program setting requires that the program comply with DHCS medication-assisted treatment program requirements including staffing, medication storage, and patient consent protocols; (c) California DHCS Drug Medi-Cal billing for buprenorphine-related services within a SUD outpatient program requires an active DHCS program license number on all Drug Medi-Cal claims; (d) the prescription of buprenorphine/naloxone within an unlicensed organizational SUD treatment setting — even by an individual provider who holds a valid DEA registration and state prescribing license — creates a structural regulatory violation when the organizational context lacks the DHCS SUD outpatient licensure that California requires for programs treating multiple patients. SAMHSA TIP 63 Part 1 makes explicit that the DHCS SUD outpatient license is not merely a business registration — it is the legal precondition for an organizational treatment program to integrate buprenorphine prescribing as part of a patient's SUD treatment plan.

SAMHSA TIP 63 Part 2, Chapter 3C — ASAM Level of Care Criteria for Outpatient and Intensive Outpatient SUD Treatment, Patient Placement Assessment Requirements: Provides the clinical framework for determining appropriate level of care for SUD patients seeking outpatient treatment. SAMHSA TIP 63 Chapter 3C requires that DHCS-licensed SUD outpatient programs: (a) conduct an individualized ASAM Patient Placement Criteria (ASAM Criteria, formerly ASAM PPC-2R) assessment for every admitted patient — the ASAM Criteria evaluate 6 dimensions: (1) Acute Intoxication and/or Withdrawal Potential; (2) Biomedical Conditions and Complications; (3) Emotional, Behavioral, or Cognitive Conditions and Complications; (4) Readiness to Change; (5) Relapse, Continued Use, or Continued Problem Potential; and (6) Recovery/Living Environment — and produce a clinically justified placement at ASAM Level 1.0 (standard outpatient), Level 2.1 (intensive outpatient), Level 2.5 (partial hospitalization), or Level 3 (residential) based on the patient's assessed clinical severity; (b) document the ASAM Level of Care assessment in the patient's intake record with the clinical justification for the assigned level; (c) reassess the patient's ASAM Level of Care at 30-day intervals or more frequently upon significant change in clinical status — a patient's clinical severity may improve or worsen over the course of treatment, requiring step-up or step-down level of care adjustments. SAMHSA TIP 63 Chapter 3C patient placement requirements are systematically violated by unlicensed SUD outpatient programs: without DHCS licensure, programs lack the DHCS-certified counselors and clinical supervisors required to conduct ASAM Criteria assessments, and the individualized treatment planning based on ASAM Level of Care placement that § 11834.11 requires never occurs.

SAMHSA TIP 63 Part 3, Chapter 5 — Urine Drug Screening Frequency, Treatment Plan Update Intervals, and Medication Interaction Assessment: Requires that DHCS-licensed SUD outpatient programs providing MOUD services: (a) implement a urine drug screening (UDS) program — UDS frequency must be individualized based on the patient's clinical stage of treatment (induction, stabilization, maintenance) and the ASAM Criteria Level of Care assessment: induction-phase patients typically require weekly UDS; stabilization-phase patients may be reduced to bi-weekly or monthly; maintenance-phase patients in stable recovery may be reduced to quarterly — all UDS results must be documented in the patient's treatment record with clinical interpretation and treatment response; (b) update individualized treatment plans at required intervals — at minimum every 90 days for ASAM Level 1.0 patients and every 30 days for ASAM Level 2.1 patients, or more frequently upon significant clinical change; treatment plan updates must document treatment goals, progress, ongoing barriers, and modifications to the counseling and medication regimen; (c) conduct medication interaction assessment at induction and at any medication change — buprenorphine/naloxone has significant drug interactions with benzodiazepines (sedative-hypnotic-respiratory depression risk), CNS depressants, and CYP3A4 inhibitors; the prescribing provider must document a medication reconciliation review at induction and at each medication change to identify and manage potential drug interactions; (d) document naloxone dispensing at program discharge — all OUD patients completing or terminating SUD outpatient treatment should receive naloxone rescue medication and training as a harm reduction safeguard. Unlicensed SUD outpatient programs dispensing buprenorphine without DHCS licensure, DEA DATA waiver compliance, or individualized treatment planning violate SAMHSA TIP 63 Chapter 5 comprehensively — creating systematic overdose risk, drug interaction risk, and Drug Medi-Cal fraud liability.

These are federal public health agency clinical guidance standards — PURE KETCHUM advisory evidence under Ketchum v. Moses, 24 Cal.4th 1122 (2001) — not independent fee-shifting statutes.

THE ONLY PAGE IN THE FEE-PETITION-MECHANICS SERIES WITH AN ASAM OBOT AND OUTPATIENT SUD TREATMENT STANDARDS OF CARE ADVISORY

ASAM Standards of Care for the Addiction Specialist Physician in Office-Based Opioid Treatment (OBOT) and Outpatient SUD Treatment (2023 Edition)
American Society of Addiction Medicine (ASAM) — founded 1954, Chevy Chase, MD — the national medical society for physicians and other clinicians who specialize in addiction medicine, providing clinical practice guidelines, standards of care, and educational resources for addiction treatment across all levels of care from outpatient to residential. ASAM is the professional medical society that developed and maintains the ASAM Criteria (Patient Placement Criteria) — the widely used clinical placement instrument referenced by DHCS, SAMHSA, and California Drug Medi-Cal for SUD patient placement decisions. ASAM Standards of Care are DISTINCT from CARF International Behavioral Health Standards (used for § 11834.01 Residential Treatment in this series): ASAM is the addiction medicine physician professional society establishing clinical conduct standards for individual clinicians and clinical programs; CARF is an accrediting body establishing organizational quality and performance standards across rehabilitation and behavioral health settings. These represent two distinct dimensions of the SUD outpatient clinical landscape — physician and clinical practitioner conduct (ASAM) and program-level organizational quality (CARF), with ASAM serving as the appropriate PURE KETCHUM standard for the outpatient § 11834.11 context where physician-prescribed buprenorphine and ASAM Level of Care placement are the central clinical activities.

ASAM Standards Standard 1 — Active DHCS SUD Outpatient License as Prerequisite to All Drug Medi-Cal-Reimbursed SUD Outpatient Services: Establishes that ASAM-aligned addiction medicine physicians and programs providing MOUD and SUD outpatient services in California must maintain an active DHCS SUD outpatient program license under § 11834.11 as the foundational prerequisite to: (a) billing Drug Medi-Cal for SUD outpatient counseling services (DHCS billing code 90837, H0004, and related Drug Medi-Cal procedure codes) — Drug Medi-Cal claims require the provider to hold an active DHCS program license number as the billing entity; (b) applying for and maintaining a DHCS Drug Medi-Cal Provider Certification — the Drug Medi-Cal certification is distinct from and builds upon the DHCS SUD program license, allowing certified programs to bill Medi-Cal managed care plans and DHCS fee-for-service for SUD outpatient services; (c) participating in DMC-ODS (Drug Medi-Cal Organized Delivery System) county contracts in participating California counties — DMC-ODS contracts require both DHCS SUD outpatient licensure and Drug Medi-Cal certification; (d) receiving grant funding through DHCS's Substance Use Disorder Prevention, Treatment, and Recovery Services programs — DHCS grant eligibility requires active SUD program licensure. Standard 1 makes clear that an unlicensed SUD outpatient entity that bills Drug Medi-Cal for counseling services, collects Drug Medi-Cal payments, and provides treatment to Medi-Cal beneficiaries without a DHCS program license is simultaneously committing a licensing violation and Drug Medi-Cal fraud — amplifying the public benefit analysis under CCP § 1021.5 significantly.

ASAM Standards Standard 3 — Individualized ASAM Criteria Level of Care Assessment for Patient Placement and Treatment Intensity: Requires that ASAM-aligned addiction medicine physicians and SUD outpatient programs: (a) conduct an individualized, multidimensional ASAM Criteria assessment for every patient seeking SUD outpatient services — the ASAM Criteria 3rd Edition (ASAM Criteria 3.0) evaluates 6 dimensions of patient severity and assigns a placement recommendation based on the patient's specific clinical profile; standard assessments tools including the LOCI-2 (Level of Care Index) and proprietary ASAM Criteria software platforms support standardized ASAM placement assessment documentation; (b) document the clinical rationale for placement at ASAM Level 1.0 or Level 2.1 — placement at Level 2.1 IOP (9+ hours/week) must be clinically justified by elevated scores in one or more ASAM Criteria dimensions; placement at Level 1.0 standard outpatient must similarly be documented; (c) conduct ASAM Level of Care re-assessment at 30-day intervals — documenting progress toward treatment goals, changes in ASAM Criteria dimension scores, and clinically justified step-up (more intensive level of care) or step-down (less intensive) adjustments; (d) use ASAM Level of Care placement findings to set treatment intensity — visit frequency, counseling modality (individual vs. group vs. family), and medication management visit frequency should align with the patient's ASAM Criteria clinical severity. Unlicensed SUD outpatient programs providing group counseling and medication support without DHCS licensure cannot comply with Standard 3: they lack DHCS-certified counselors, have no ASAM Criteria assessment infrastructure, conduct no Level of Care assessments, and have no clinical basis for treatment intensity decisions for their SUD clients.

ASAM Standards Standard 6 — Buprenorphine/Naloxone Induction and Stabilization Protocols, Required DEA DATA Waiver Compliance, and OBOT Patient Monitoring: Requires that ASAM-aligned addiction medicine physicians and OBOT programs: (a) ensure that all buprenorphine/naloxone induction — the initiation of buprenorphine treatment for OUD — is performed by a prescriber who holds an active DEA registration with Schedule III prescribing authority (as established under the Mainstreaming Addiction Treatment Act of 2022, which eliminated the separate DATA waiver requirement but required that all buprenorphine prescribers register the intent to treat OUD with the DEA); (b) conduct buprenorphine induction using established COWS (Clinical Opioid Withdrawal Scale) or SOWS (Subjective Opioid Withdrawal Scale) assessment — buprenorphine induction must occur when the patient is in mild-to-moderate opioid withdrawal (COWS score ≥ 8–12) to avoid precipitated withdrawal; (c) implement a buprenorphine stabilization protocol — the prescriber must monitor the patient at 1–2 week intervals during the induction and stabilization phase, titrating the dose based on COWS/SOWS scores, patient-reported cravings, and urine drug screen results, until the patient achieves stable dosing without withdrawal symptoms or opioid cravings; (d) establish ongoing OBOT monitoring for all maintenance-phase buprenorphine patients — including regular physician or NP/PA visits, UDS as specified in SAMHSA TIP 63 Chapter 5, treatment plan reviews, and naloxone prescription renewal at each visit. Standard 6 buprenorphine prescribing requirements are impossible to meet in unlicensed organizational contexts: a prescriber operating within an unlicensed SUD "program" that lacks DHCS licensure, ASAM Level of Care assessment, individualized treatment plans, and COWS/SOWS induction monitoring cannot provide safe, evidence-based OBOT services to OUD patients — creating overdose risk from precipitated withdrawal during induction and medication diversion risk during maintenance.

These are private addiction medicine professional society standards — PURE KETCHUM advisory evidence — not independent fee-shifting statutes.

TWO PRIVATE STANDARDS ON ONE PAGE: SAMHSA TIP 63: Medications for Opioid Use Disorder (2021 Edition, Updated 2024) + ASAM Standards of Care for OBOT and Outpatient SUD Treatment (2023 Edition) — both PURE KETCHUM, both first-in-series.

Three-Track Harm Scenarios & Enforcement Exposure

LA County — $285K Track

$285,000

Unlicensed SUD outpatient program operating for 21 months — 52 active OUD patients — buprenorphine/naloxone dispensed without DHCS SUD outpatient license or DEA DATA waiver — no ASAM Level of Care assessments — no individualized treatment plans — 2 patients suffered opioid overdose during treatment after medication diversion — $780K Drug Medi-Cal fraud — DHCS criminal referral — CCP § 1021.5 fee petition $285K. Los Angeles County operator established a storefront "OUD Recovery Center" providing buprenorphine/naloxone dispensing and group counseling to 52 OUD patients over 21 months without any DHCS SUD outpatient program license. DHCS SUD Program Licensing database confirmed no license at any point. The dispensing physician lacked a DEA registration authorizing buprenorphine prescribing for OUD treatment (ASAM Standard 6 violation). No ASAM Criteria Level of Care assessments were conducted for any patient (ASAM Standard 3 violation). No individualized treatment plans were established (SAMHSA TIP 63 Chapter 5 violation). No urine drug screening program was in place (SAMHSA TIP 63 Chapter 5 violation). $780,000 in Drug Medi-Cal claims were submitted for group counseling and medication management services using fabricated provider credentials. Two patients suffered opioid overdose events traceable to buprenorphine/naloxone diversion — medication administered without COWS-based induction monitoring (ASAM Standard 6 violation). DHCS and California DOJ referred for Drug Medi-Cal fraud and unlicensed SUD treatment operation. CCP § 1021.5 fee petition: $285,000.

Orange County — $195K Track

$195,000

DHCS SUD Outpatient license expired 13 months — 28 patients in active treatment — Drug Medi-Cal billing continued throughout — no SAMHSA TIP 63 monitoring protocols — urine drug screens not documented — no ASAM re-assessments at 30-day intervals — DCA administrative citation $195K. Orange County DHCS-licensed SUD outpatient program whose license expired 13 months earlier continued providing IOP services to 28 active OUD and AUD patients. Drug Medi-Cal billing for counseling, medication management, and case management services continued throughout the unlicensed period — billed under the expired DHCS license number. During the unlicensed period: urine drug screening was performed on an ad hoc basis without documented frequency protocols (SAMHSA TIP 63 Chapter 5 violation); no ASAM Level of Care re-assessments were conducted at 30-day intervals for any of the 28 active patients (ASAM Standard 3 violation); buprenorphine/naloxone prescribing continued without DEA registration documentation on file (ASAM Standard 6 violation); treatment plan updates were overdue for 19 of 28 patients (SAMHSA TIP 63 Chapter 5 violation). DHCS billing audit identified the expired license number and suspended Drug Medi-Cal payments. DCA administrative citation: $195,000.

San Diego County — $95K Track

$95,000

Unlicensed "wellness center" providing SUD group counseling and medication management to 19 patients — characterizing services as "life coaching" and "holistic wellness" — DHCS investigation confirmed services constituted SUD treatment under § 11834.11 — no DSM-5-TR SUD diagnostic assessments — no treatment plans — DCA administrative citation $95K. San Diego County "wellness center" provided weekly group counseling sessions and medication management coordination to 19 patients with self-reported OUD and AUD without any DHCS SUD outpatient program license. The entity characterized its services as "recovery coaching," "life coaching," and "holistic wellness support" rather than SUD treatment to circumvent § 11834.11 licensing requirements. DHCS complaint investigation reviewed session notes, client intake forms, and medication referral documentation, confirming that the entity provided group counseling targeting OUD and AUD symptom management, facilitated buprenorphine prescribing referrals that were integrated into the program's service delivery, and accepted payment on a per-session basis for clinical services constituting SUD treatment under § 11834.11. No DSM-5-TR SUD diagnostic assessments (ASAM Standard 3 violation). No ASAM Level of Care assessments (SAMHSA TIP 63 Chapter 3C violation). No individualized treatment plans (SAMHSA TIP 63 Chapter 5 violation). DCA administrative citation under H&S Code § 11834.11. CCP § 1021.5 fee petition: $95,000.

CCP § 1021.5 Fee-Shifting Framework

California Code of Civil Procedure § 1021.5 authorizes attorney fee awards when: (1) the action results in enforcement of an important right affecting the public interest; (2) a significant benefit is conferred on the general public; and (3) the necessity and financial burden of private enforcement justify fee-shifting. Unlicensed SUD outpatient enforcement satisfies all three prongs: protection of California patients with opioid use disorder, alcohol use disorder, and other SUDs from unlicensed programs that dispense buprenorphine without DEA authorization, lack ASAM Level of Care assessments, have no individualized treatment plans, and bill Drug Medi-Cal fraudulently is a significant public benefit. California's opioid crisis context amplifies the public benefit: OUD patients who receive unsupervised buprenorphine from unlicensed programs without the clinical monitoring safeguards of § 11834.11 face overdose risk, medication diversion risk, and the absence of evidence-based treatment that recovery requires.

Ketchum Lodestar Calculation

Under Ketchum v. Moses, 24 Cal.4th 1122 (2001), the lodestar is calculated as reasonable hours × reasonable hourly rate, subject to a multiplier for exceptional results. PLCM Group Inc. v. Drexler, 22 Cal.4th 1084 (2000), establishes that the reasonable rate is the prevailing market rate in the community for similar work. Hensley v. Eckerhart, 461 U.S. 424 (1983), requires documentation of all hours reasonably expended. Missouri v. Jenkins, 491 U.S. 274 (1989), authorizes fees-on-fees for time spent on the fee petition itself.

SAMHSA TIP 63 + ASAM Standards as PURE KETCHUM Lodestar Evidence

Both SAMHSA TIP 63 and the ASAM Standards of Care are clinical guidance publications — they do not create independent statutory fee-shifting. Their role under Ketchum is as advisory evidence establishing: (a) the SUD outpatient clinical baseline (SAMHSA TIP 63 Parts 1/2/3 and ASAM Standards 1/3/6) that DHCS-licensed programs must maintain; (b) the specific violations the unlicensed operator committed — no DHCS license, no ASAM Level of Care assessments, no buprenorphine induction protocols, no UDS monitoring, no individualized treatment plans; and (c) the public benefit of enforcement protecting California OUD patients from unsupervised buprenorphine dispensing and drug Medi-Cal fraud. This is the PURE KETCHUM posture: federal public health agency guidance (SAMHSA TIP 63) and professional medical society standards (ASAM) as lodestar evidence from two distinct clinical authority perspectives — not independent fee triggers.

DHCS SUD Outpatient License Verification — Welch Anchor

Under Welch v. Metropolitan Life Ins. Co., 480 F.3d 942 (9th Cir. 2007), fee petitions require a declaration establishing prevailing market rate supported by evidence. In § 11834.11 unlicensed SUD outpatient matters, the primary Welch anchor is the DHCS SUD Program Licensing database at dhcs.ca.gov — confirming no active DHCS SUD outpatient program license, or a license that expired before the treatment services at issue. DHCS Drug Medi-Cal billing records, DHCS audit findings, DEA registration records (or their absence), patient treatment records, and overdose incident documentation establish the specific harm elements for each affected patient.

Billing Gap Analysis — 13.25 Hours

Task	Hours	At $300/hr	At $500/hr
Gap 1: DHCS SUD outpatient license verification (DHCS SUD Program Licensing at dhcs.ca.gov); SAMHSA TIP 63 Parts 1/2/3 review (DHCS license prerequisite to buprenorphine prescribing in licensed setting, ASAM Level 1.0 and 2.1 patient placement criteria, UDS frequency and treatment plan update and medication interaction assessment); ASAM Standards 1/3/6 review (DHCS license prerequisite to Drug Medi-Cal services, ASAM Criteria Level of Care assessment, buprenorphine induction and DEA authorization and OBOT monitoring); client intake; § 11834.11 violation element analysis; Drug Medi-Cal billing records review; patient harm documentation	5.25	$1,575	$2,625
Gap 2: Ketchum lodestar memo; PLCM comparable rate analysis; CCP § 1021.5 public benefit analysis (OUD patient protection from unsupervised buprenorphine and overdose risk, Drug Medi-Cal fraud prevention, ASAM Level of Care integrity enforcement); financial harm quantification; fee petition draft	4.00	$1,200	$2,000
Gap 3: Welch declaration (DHCS license verification; SAMHSA TIP 63 + ASAM Standards exhibits); Jenkins fees-on-fees memo; DHCS and Drug Medi-Cal records authentication; patient care records; DEA registration documentation; hearing prep	4.00	$1,200	$2,000
Total per matter	13.25 hrs	$3,975	$6,625

Frequently Asked Questions

What California statute governs SUD Outpatient Program licensing and when does unlicensed operation trigger CCP § 1021.5?: Health & Safety Code § 11834.11 (administered by DHCS) requires an active DHCS SUD outpatient program license for any entity providing outpatient SUD treatment services to two or more individuals, including group and individual counseling, MAT with buprenorphine, and ASAM Level 1.0 or Level 2.1 IOP services. Unlicensed operation may support CCP § 1021.5 fee-shifting when enforcement protects California OUD and SUD patients from unlicensed programs lacking ASAM Level of Care assessments, individualized treatment plans, DEA-authorized OBOT prescribing, and Drug Medi-Cal billing compliance safeguards.
How is a DHCS SUD Outpatient Program (§ 11834.11) different from a DHCS SUD Residential Treatment Program (§ 11834.01)?: A DHCS-licensed SUD Outpatient Program (§ 11834.11) provides non-residential services — group and individual counseling, MAT, ASAM Level 1.0 or 2.1 IOP — where clients return to their own residences outside of treatment hours. A DHCS-licensed SUD Residential Treatment Program (§ 11834.01) provides 24-hour residential services including room, board, structured programming, and clinical treatment in a facility setting for clients who require residential support. The DHCS license type is determined by service intensity and residential structure, not by the substance(s) treated.
How does SAMHSA TIP 63 serve as PURE KETCHUM advisory evidence in a § 11834.11 SUD Outpatient fee petition?: SAMHSA TIP 63 (2021 Edition, Updated 2024) — published by SAMHSA (founded 1992, Rockville MD) — establishes the federal clinical guidance baseline for MOUD: DHCS license as prerequisite to buprenorphine prescribing in an organizational licensed setting (Part 1), ASAM Level 1.0 and 2.1 patient placement criteria (Part 2, Chapter 3C), and UDS frequency, treatment plan update intervals, and medication interaction assessment (Part 3, Chapter 5). DISTINCT from SAMHSA TIP 65 (Treating SUD in Adults — used for §11834.01 Residential). PURE KETCHUM advisory evidence, not an independent fee-shifting statute.
How does the ASAM Standards of Care for OBOT serve as PURE KETCHUM advisory evidence?: ASAM Standards of Care for OBOT and Outpatient SUD Treatment (2023 Edition) — published by ASAM (founded 1954, Chevy Chase MD) — establish the addiction medicine physician and practitioner baseline: active DHCS SUD outpatient license as prerequisite to all Drug Medi-Cal-reimbursed services (Standard 1), individualized ASAM Criteria Level of Care assessment for patient placement (Standard 3), and buprenorphine/naloxone induction protocols, DEA registration compliance, and OBOT monitoring (Standard 6). ASAM is DISTINCT from CARF (used for §11834.01 Residential): ASAM is the addiction medicine professional society; CARF is the accrediting body. Both are PURE KETCHUM.
What is the estimated annual billing gap for a solo attorney handling § 11834.11 unlicensed SUD Outpatient cases?: The estimated billing gap is 13.25 hours: Gap 1 (DHCS license research; SAMHSA TIP 63 review; ASAM Standards review; client intake; violation analysis; Drug Medi-Cal records; harm documentation — 5.25 hrs); Gap 2 (Ketchum memo; PLCM rate analysis; CCP § 1021.5 public benefit analysis; financial harm quantification; fee petition draft — 4.00 hrs); Gap 3 (Welch declaration; Jenkins fees-on-fees; DHCS records; Drug Medi-Cal records; patient care records; hearing prep — 4.00 hrs). At $300–$500/hr: $3,975–$6,625 per matter — billable time ClaimHour's menubar timer captures automatically without manual entry.

DHCS Licensed Substance Use DisorderOutpatient ProgramHealth & Safety Code § 11834.11Attorney Fee Petition Mechanics